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Introduction
Autism spectrum disorders (ASDs) are a group of neurodevelopmental disorders characterized
by impaired social communication, abnormal language development, restricted interests, and
repetitive and stereotyped behaviors (Zoghbi and Bear, 2012; Ebert and Greenberg, 2013; Lai et al.,
2014). These disorders show a high degree of clinical and genetic heterogeneity. Studies suggest
that there is the functional convergence among autism-linked genes on common pathways that are
involved in synaptic development, plasticity and signaling, raising the hope that similar therapeutic
strategy may be effective for different forms of autistic disorders (Krumm et al., 2014; Ronemus
et al., 2014). Investigation of cellular and synaptic deficits in ASDs will provide further insights into
the pathogenesis of autism and may eventually lead to potential treatment for autism and other
neurodevelopmental disorders (Zoghbi and Bear, 2012; Delorme et al., 2013; Ebert and Greenberg,
2013).
Our research topic entitled Neural and Synaptic Defects in Autism Spectrum Disorders,
brings together 23 articles which document the recent development and ideas in the study of
molecular/cellular mechanisms and treatment of ASDs, with an emphasis on syndromic disorders
such as fragile X and Rett syndromes. In addition, model systems and methodological approaches
with translational relevance to autism are covered in this research topic.
Molecular, Synaptic and Cellular Deficits in ASDs
Fragile X and Rett syndromes are leading the way in investigating the molecular mechanisms of
autism (Krueger and Bear, 2011; Katz et al., 2012; Santoro et al., 2012). Fragile X mental retardation
protein (FMRP) is an mRNA binding protein absent or mutated in fragile X syndrome (Bhakar
et al., 2012; Santoro et al., 2012; Wang, 2015). Westmark highlights a study which demonstrated
how FMRP cooperates with other autism-related molecules in experience-dependent synaptic
pruning through proteasome-mediated degradation of postsynaptic density 95 (PSD-95) and how
that mechanism fails in fragile X syndrome (Tsai et al., 2012;Westmark, 2013). FMRP interacts with
other proteins, such as Slack channels and cytoplasmic FMRP interacting protein 1/2 (CYFIP1/2)
(Pasciuto and Bagni, 2014). Abnormal Slack channel activity is implicated in fragile X syndrome.
Kim andKaczmarek describe the physiological role of Slack channels and how altered Slack channel
activity leads to intellectual disability (Kim and Kaczmarek, 2014). Abekhoukh and Bardoni review
the potential roles of CYFIP1/2 in intellectual disability and autism, and their relation to fragile X
syndrome (Abekhoukh and Bardoni, 2014).
Wang and Doering Autism spectrum disorders: mechanisms and treatment
Rett syndrome is primarily caused by mutations in the
methyl-CpG-binding protein 2 (MECP2) gene encoding the
transcriptional repressor MeCP2 (Moretti and Zoghbi, 2006;
Chahrour and Zoghbi, 2007). Xu and Pozzo-Miller comment on
a study which identified a novel AT-hook domain of MeCP2
that plays important roles in chromatin organization, providing a
mechanism that determines the clinical course of Rett syndrome
and related disorders (Baker et al., 2013; Xu and Pozzo-Miller,
2013). The post-translational modifications of MeCP2 generate
and regulate its functional versatility. Bellini et al. provide an
overview of post-translational modifications as a mechanism
for MeCP2 to control its involvement in synaptic plasticity
and homeostasis (Bellini et al., 2014). The methyl-CpG-binding
domain (MBD) of MeCP2 is crucial for its function as a
transcriptional repressor. Zhao et al. provide further evidence
from cultured hippocampal neurons and in vivo newborn
neurons that mutations of MBD affect the roles of MeCP2 in
neuronal development (Zhao et al., 2015).
Investigating the genes and genetic pathways involved in
ASDs is essential to unraveling the pathogenesis of these
disorders (Krumm et al., 2014; Ronemus et al., 2014). Banerjee
et al. review how studies using animal models are providing
key information for ASDs and discuss the genetic aspects of
ASDs, emphasizing the conserved genes and genetic pathways
implicated in autism (Banerjee et al., 2014). Chen et al.
summarize the defects of synaptic proteins and receptors linked
to ASDs and discuss their roles in the pathogenesis of ASDs via
synaptic pathways (Chen et al., 2014).
Deficits in synapses and neural circuits underlie cognitive
dysfunction in ASDs (Zoghbi and Bear, 2012; Ebert and
Greenberg, 2013). Martin and Manzoni report that synaptic
abnormalities persist into adulthood in the valproic acid rat
model of autism and point out that the switch from hyper
to hypo function in the medial prefrontal cortex might be
related to neurodevelopmental defects in ASDs (Martin and
Manzoni, 2014). Rotschafer and Razak review the auditory
processing in fragile X syndrome, suggesting that auditory
hypersensitivity could be a biomarker for fragile X syndrome
and other ASDs (Rotschafer and Razak, 2014). Neuhofer et al.
report on deficits in synaptic plasticity and dendritic spines
within the nucleus accumbens of fragile X mice (Neuhofer
et al., 2015). Doll and Broadie document the impairments in
activity-dependent neural circuit assembly and refinement in
ASD genetic models, particularly in the drosophila fragile X
model (Doll and Broadie, 2014). Cea-Del Rio and Huntsman
review how interneuron populations and inhibition contribute
to the excitatory/inhibitory imbalance of neural networks in
fragile X syndrome (Cea-Del Rio and Huntsman, 2014). Port
et al. describe the convergence of circuit dysfunction in ASDs
and discuss how studies focusing on neural circuit function help
to identify common neurobiological mechanisms of ASDs (Port
et al., 2014).
The advances in technical approaches and disease models
have provided unprecedented opportunities to investigate neural
and synaptic deficits in ASDs. In addition to mouse and rat
models, other animals such as drosophila and C. elegans are now
used to study autism (Doll and Broadie, 2014; Gamez-Del-Estal
et al., 2014). The induced pluripotent stem cell (iPSC) technology
combined with neural differentiation techniques allows detailed
functional analysis of neurons generated from living individuals
with neurological disorders (Bellin et al., 2012; Wang and
Doering, 2012). In this research topic, Kim et al. summarize
recent achievements in differentiating cortical neurons from
human iPSCs and efforts to establish cell model systems to study
ASDs using personalized neurons (Kim et al., 2014).
Mechanism-based Treatment
Pharmacological manipulation of neurotransmitter systems or
signaling pathways linked to ASDs may provide therapeutic
benefits for patients (Delorme et al., 2013; Ebert and Greenberg,
2013). Wang and Doering comment on a study which showed
that targeting the downstream mTOR signaling pathway rectifies
social behavior deficits in autistic mice (Gkogkas et al., 2013;
Wang and Doering, 2013). The pharmacotherapy for fragile X
and Rett syndromes is the focus of this research topic. The
metabotropic glutamate receptor 5 (mGluR5) has been identified
as a potential target for treating fragile X syndrome (Bhakar
et al., 2012; Wang and Zhuo, 2012; Scharf et al., 2015). Gandhi
et al. report that mGluR5 antagonist MPEP reverses maze
learning and PSD-95 deficits in fragile X mice (Gandhi et al.,
2014). The serotonin (5-HT) transporter inhibitor fluoxetine
is prescribed for children with autism. Uutela et al. further
document the behavioral and cellular responses to fluoxetine
in the mouse model for fragile X syndrome (Uutela et al.,
2014). Ciranna et al. review the potential therapeutic significance
of 5-HT7 receptors for fragile X syndrome and other ASDs
(Ciranna and Catania, 2014). Janc and Muller report that the free
radical scavenger Trolox attenuates neuronal hyperexcitability,
restores synaptic plasticity, and improves hypoxia tolerance in
the hippocampal slices ofMecp2−/y mice, suggesting that radical
scavengers might be an option for treating neuronal dysfunction
in Rett syndrome (Janc and Muller, 2014). Xu et al. report
that the histone deacetylase-6 inhibitor Tubastatin-A improves
BDNF trafficking in hippocampal neurons fromMecp2 knockout
mice, demonstrating that histone deacetylase-6 is a potential
pharmacological target for treating Rett syndrome (Xu et al.,
2014).
Lastly, Wang et al. provide a comprehensive review of current
targeted pharmacological treatments for fragile X and Rett
syndromes, and discuss related issues in both preclinical and
clinical studies of potential therapies for ASDs (Wang et al.,
2015). Since there are significant neurobiological overlaps among
ASDs, the targeted treatments developed for fragile X and Rett
syndromes will be highly relevant to other autistic disorders.
Perspective
The increasing need for effective treatment of ASDs, together
with the advancement of disease models and other technologies,
are promoting studies toward identifying potential therapies.
It is inspiring to see that research in animal models is
translating into patients with ASDs. The successful development
of mechanism-based treatment for autism will continuously
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require more extensive multidisciplinary collaboration among
different research sectors (Katz et al., 2012; Delorme et al., 2013;
Wang, 2014).
We thank the authors and reviewers for their efforts and
hope that this research topic will enrich our knowledge of
ASDs and spur new research interests in autism related
biology.
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